a healthy brain for life - resi longevity

© 2020 Mitocholine Ltd - All rights reserved

Mitocholine™

A Healthy Brain For Life

Dementia - The #1 health concern for 42% of population.

Mitocholine™ in the daily diet for a healthy brainthroughout life

Unique Investment Opportunity in Cognitive Decline Market

Mitocholine™ -

A BreakthroughNew

Compound


Mitocholine™

The ProblemAgeing Population escalates numbers suffering

from Dementia

Source: Alzheimers Research UK

50,000,000

150,000,000

0

40

80

120

160

Y2019 Y2050

Milli

ons

of P

eopl

e

Region Economic Cost of Dementia (2018)

UK £26bn

EU €220bn

US $290bn

AsiaPac $200bn

Globally $1000bn

Spiralling Economic Cost

$6600bn by

Y2050

Ø Nobody knows WhoØ Everybody’s at risk

Ø No Present SolutionØ Huge unmet Need


Mitocholine™

200,000,000

700,000,000

Dementia

Cognitive Impairment

Worried Well

Our Target Markets50,000,000

The OpportunityDementia #1 Health Concern for 42% of Population

Sources: Alzheimers Research UK and Pew Research Center

1

2

Huge market: Ø Population with early stage cognitive declineØ Those very concerned (42% of Population)


Mitocholine™

The Science

Source: Stephen C. Cunnane et al, Brain Energy Rescue, Nature Review

Mitocholine™ addresses dysfunctional brain cell energetics, a key factor in cognitive decline

https://youtu.be/qIohuf6k82QExplanatory video:

Brain energy gap

Brain cell dysfunction

Ø AgeØ LifestyleØ Genes

Ø Memory lossØ MCIØ Dementia

Increases

Increases

MitocholineTM breaks the vicious cycle by

rescuing brain energy

Vicious..

..Cycle

https://youtu.be/qIohuf6k82Q


Mitocholine™

The SolutionMitocholine™ Choline Succinate salt Nicotinamide= : +

ATP NADH

Patented Ratio

BreakthroughSynergistic

Effect

Pre-clinical Findings Pre-clinical Findings

Mitocholine™ dramatically improves key markers of mitochondrial energy production


Mitocholine™

IP Protection• Patent Application Filed 2017

• IPA* search found invention novel & non-obvious

• Patent Grants expected from 2022

• Freedom to Operate

• IP Protection until 2038*IPA – International Patent Authority


Mitocholine™

CommercialisationPrimary target markets are medical foods/FSMP and nutritional products

Medicated Gummies& Lozenges

Capsules& tablets*

*Requires R&D for powdered production

Ø Nutritional approach ideally suited for long-term-, chronic interventions...

Ø ...with high-end categories by strategic partners with global reach

Nutritional Dairy Products

MedicatedDrinks

NutritionalBeverages


Mitocholine™

Route to MarketPatent Protection

2019 2020 2021 2022 2023 2024 2025

US GRAS/EFSA Novel Food Dossier & ApprovalRound A Fund Raising (Venture Arms Strategic Partner Candidates)

Launch Product

Patent Approval

Clinical Trials PoC(MCI Patients)

WO 2019/002858

2026 2027

Prod. Dev. w/Strategic Partners

Commercial/Sales to Strategic Partners

Submitted

1 2 3 4

1 US

2 UK

3 EU5

4 AsiaPac

(Order may change)

Medical Foods/FSMP much quicker than Pharma

route


Mitocholine™

Attractive Business Plan

-

20,000

40,000

60,000

80,000

100,000

120,000

140,000

160,000

180,000

200,000

2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031

Unit Sales(x 1,000)

US UK EU5 APAC

Based on standard medical food values and Kantar Health models

Reason to believe: 2031 sales represents a realistic penetration of 2.6% of mild cognitive impairment market

Based on normative Medical Food/FSMP assumptions


Mitocholine™

-

50,000

100,000

150,000

200,000

250,000

300,000

350,000

2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031

Retail Revenue(x £1,000)

US UK EU5 APAC

× 15 ≈ £120m valuationRound A

£3m

Ø Investment of £3 million required to complete clinical trial and regulatory approvalsØ Exit opportunities in 3 to 5 years upon completion of 1st clinical study and initial partnership deals

Attractive Business PlanBased on normative Medical Food/FSMP assumptions


Mitocholine™

The Team Who Can Deliver

Daniel AnthonyProfessor Oxford

Andrey AbramovProfessor UCL

Advisory Board

Key Collaborators

20+ years of experience in FMCG and nutrition companies, including:• Formulating and executing corporate

innovation and IP strategies• Starting and growing businesses• Leading multifunctional teams

involving research, marketing, finance, IP and M&A.

(Nestlé, Glycom)

Bruce McConnellChairman of the Board

Simon BaldryCOO

More than 20 years of experience as Managing Director / General Manager in the Food & Drink Industry(Coca Cola, Cadbury)

Larisa Andreeva, PhD, Founder/CEO

25 years experience from biochemresearch and research programmemanagement (Imperial College London, UCL)

Igor Pomytkin, PhD, Founder/Chief Scientist

35+ years experience in neuroscientific research. More than 30 patents to his name (University of Oxford, University of Moscow) of which several have become commercial products.

Galina SkladchikovaPhD, Founder,

Head of IP

20+ years experience in:• Scientific research in the fields of

biochemistry, molecular and cell biology;

• Strategic IP development and management;

• Implementation of IP in innovation and business;

(Glycom, Dako, Hoiberg).Christian Barnes

Dir. Licensing

15yrs experience in product innovation and business development, including BD director of Nestle Health's Science Brain Health platform (Pamlab, Nestle, Akebia)

Prototype Dev. & Testing

Clinical Trials

Regulatory Specialist


Mitocholine™

For further info please contact :Larisa Andreeva at [email protected]

Thank you!

A Healthy Brain For LifeØ Will deliver massive

improvement in quality of life for patient and family

Ø A high-, unmet-, growing need.

Ø A breakthrough solution with excellent initial data and IP.

Ø Unparallelled benefits for society

Ø Lower risk-, rapid (non-pharma) route to market.

Ø A team who can deliver

Ø Many-fold ROI opportunity with superb exit opportunity in 3 to 5 years.

a healthy brain for life - resi longevity

Documents